David Lockhart
Director at Centocor | Wayne, Pennsylvania, United States
David Lockhart’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Product Director at Centocor/Johnson & Johnson in January 2006 - Present
Director at Centocor
Product Director at Johnson & Johnson (Centocor Ortho Biotech) in January 1999 - January 2010
William & Mary, January 1985 to January 1989
Subsidiary of Johnson & Johnson, Centocor is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal antibody technology. In 1982 Centocor developed their first product approved by the U.S. Food and Drug Administration (FDA) — a diagnostic test used to detect the rabies virus, and in that same year transitioned into a publicly traded company. Subsequently, the company moved to a larger facility in Malvern, Pennsylvania (a northwest suburb of Philadelphia). In 1984, Centocor opened an overseas plant in Leiden, the Netherlands. Eighteen years after its foundation, (in 1997), Centocor achieved its first year of operating profitability. In 1998, Centocor divested itself of its diagnostic division and launched its top-selling monoclonal antibody Remicade (infliximab) for its first FDA approved indication in Crohn's Disease. In 1999, Centocor became a wholly owned subsidiary of Johnson & Johnson, the worldwide manufacturer and marketer of healthcare products. Subsequently, Remicade's market has expanded with approvals for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and pediatric Crohn's disease. Remicade was approved for plaque psoriasis in September 2006. Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA). Since being acquired by Johnson and Johnson, Centocor has increased its annual sales from approximately $500 million to more than $2 billion. During the same period, research and development investment increased from $75 million to more than $300 million. In 2004 Centocor purchased a new manufacturing plant in St. Louis, Missouri, and is currently opening a new manufacturing facility in County Cork, Ireland. The Dutch plant has been expanded substantially with a $250 million investment in additional production facilities, which were opened in 2006.
Discover more about CentocorAssistant Director at Centocor
Assistant Director at Centocor R&D (Johnson & Johnson)
(January 2002 – Present)
TFA (STEM teacher); (retired) RMAT, Scientific Innovation Projects_Global Regulatory Affairs (Bridges). Senior Scientist/ADTO at Janssen R&D
Scientist at Janssen R&D
(January 2002 – Present)
Senior Associate at Centocor
Scientist at Centocor
(January 2001 – Present)
Sr. Executive ISG at Janssen Biotech
Sr ISG at Centocor
(Present)
Experience Pharma Industry Project Manager
Dir. of Collaborations Management at Centocor, subsidiary of Johnson & Johnson
(January 2005 – Present)
Associate Scientist II at Janssen R&D, Inc.
Associate Scientist II at Centocor, Johnson and Johnson
(January 2001 – Present)
What is David Lockhart email address?
Email David Lockhart at [email protected]. This email is the most updated David Lockhart's email found in 2026.
How to contact David Lockhart?
To contact David Lockhart send an email to [email protected].
What company does David Lockhart work for?
David Lockhart works for Centocor.
What is David Lockhart's role at Centocor?
David Lockhart is Director
What industry does David Lockhart work in?
David Lockhart works in the Pharmaceuticals industry.